ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage

ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage

ACST
-1.84%
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is giving an update on the usage of the “at the market” equity of its providing program.

As previously disclosed, Acasti entered into an amended and restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. along with H.C. Wainwright & Co., LLC (collectively, the “Agents”), to implement an “at-the market” equity offering program under which Acasti might issue and promote from time to time the everyday shares of its having an aggregate offering price of up to seventy five dolars million throughout the Agents (the “ATM Program”).

ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the end distributions reported on January 27, 2021, Acasti issued an aggregate of 20,159,229 common shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 zillion. The ATM Shares ended up being offered at prevailing market prices averaging US$1.0747 a share. No securities had been sold throughout the facilities of the TSXV or perhaps, to the knowledge of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S 3 (No. 333-239538) as made effective on July seven, 2020, and the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate yucky proceeds raised was given to the Agents in connection with the services of theirs. As a consequence of the recent ATM sales, Acasti has a total of 200,119,659 typical shares issued and great as of March 5, 2021.

The extra capital raised has strengthened Acasti’s balance sheet and will deliver the Company with more flexibility in its continuous review process to explore and evaluate strategic options.

Approximately Acasti – ACST Stock

Acasti is actually a biopharmaceutical innovator that has historically centered on the research, commercialization and development of prescription medications making use of OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have substantial clinical evidence of safety and efficacy for lowering triglycerides in individuals with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being created for individuals with severe HTG.

Forward Looking Statements – ACST Stock

Statements of that press release which aren’t statements of current or historical truth constitute “forward looking information” to the meaning of Canadian securities laws and “forward looking statements” within the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward looking claims involve known and unknown risks, uncertainties, along with other unknown variables that can cause the particular results of Acasti to be materially different from historical success and as a result of any future outcomes expressed or implied by such forward-looking statements. In addition to statements which explicitly describe these types of risks and uncertainties, people are actually urged to look at statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other related expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak simply as of the particular date of this press release. Forward-looking claims in this press release include, but aren’t limited to, statements or info concerning Acasti’s strategy, succeeding operations and its review of strategic alternatives.

The forward-looking assertions contained in this press release are expressly qualified in their entirety by this alerting declaration, the “Special Note Regarding Forward Looking Statements” section in Acasti’s latest annual report on Form 10 K and quarterly report on Form 10 Q, which are actually readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and also on the investor area of Acasti’s site at www.acastipharma.com. All forward-looking claims in that press release are manufactured as of the day of this particular press release.

ACST Stock – Acasti does not undertake to upgrade any such forward-looking statements whether as a consequence of info which is brand new, future events or even otherwise, except as called for by law. The forward-looking statements contained herein are also subject typically to risks and assumptions and uncertainties that are actually described from time to time in Acasti’s public securities filings with the Securities and The Canadian and exchange Commission securities commissions, including Acasti’s newest annual report on Form 10 K and quarterly report on Form 10-Q underneath the caption “Risk Factors“.

 

ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage

Comments are Disabled